Christopher Longshaw

3.2k total citations
56 papers, 1.9k citations indexed

About

Christopher Longshaw is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Christopher Longshaw has authored 56 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Medicine, 23 papers in Pharmacology and 19 papers in Epidemiology. Recurrent topics in Christopher Longshaw's work include Antibiotic Resistance in Bacteria (25 papers), Antibiotics Pharmacokinetics and Efficacy (23 papers) and Antibiotic Use and Resistance (19 papers). Christopher Longshaw is often cited by papers focused on Antibiotic Resistance in Bacteria (25 papers), Antibiotics Pharmacokinetics and Efficacy (23 papers) and Antibiotic Use and Resistance (19 papers). Christopher Longshaw collaborates with scholars based in United Kingdom, Japan and United States. Christopher Longshaw's co-authors include Mark H. Wilcox, Jane Freeman, Scott Nicholson, Jon J. Vernon, K. Morris, Davide Manissero, S. L. Todhunter, Yoshinori Yamano, Anne Santerre Henriksen and Helen Ashwin and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and CHEST Journal.

In The Last Decade

Christopher Longshaw

54 papers receiving 1.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Christopher Longshaw 907 722 651 415 362 56 1.9k
Maria Karlsson 921 1.0× 607 0.8× 429 0.7× 130 0.3× 346 1.0× 57 1.7k
Camilla Wiuff 616 0.7× 459 0.6× 635 1.0× 273 0.7× 288 0.8× 34 1.6k
Paul Lephart 947 1.0× 937 1.3× 941 1.4× 485 1.2× 425 1.2× 75 2.4k
Eduardo Rodríguez-Noriega 991 1.1× 767 1.1× 753 1.2× 222 0.5× 604 1.7× 110 2.3k
Deborah C. Draghi 783 0.9× 513 0.7× 742 1.1× 447 1.1× 362 1.0× 33 1.9k
Francesco Cristini 831 0.9× 925 1.3× 1.1k 1.7× 941 2.3× 154 0.4× 59 2.5k
Rayo Morfín‐Otero 683 0.8× 439 0.6× 661 1.0× 158 0.4× 546 1.5× 102 1.8k
Élisabeth Chachaty 773 0.9× 727 1.0× 614 0.9× 149 0.4× 373 1.0× 56 1.9k
Mark LaRocco 606 0.7× 770 1.1× 386 0.6× 189 0.5× 253 0.7× 61 1.9k
Dee Shortridge 528 0.6× 768 1.1× 1.3k 2.0× 800 1.9× 310 0.9× 85 2.6k

Countries citing papers authored by Christopher Longshaw

Since Specialization
Citations

This map shows the geographic impact of Christopher Longshaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Longshaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Longshaw more than expected).

Fields of papers citing papers by Christopher Longshaw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Longshaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Longshaw. The network helps show where Christopher Longshaw may publish in the future.

Co-authorship network of co-authors of Christopher Longshaw

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Longshaw. A scholar is included among the top collaborators of Christopher Longshaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Longshaw. Christopher Longshaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reynolds, Rosy, Shazad Mushtaq, Russell Hope, et al.. (2025). Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019. Journal of Antimicrobial Chemotherapy. 80(Supplement_4). iv22–iv35. 1 indexed citations
2.
3.
Reynolds, Rosy, D. Felmingham, Shazad Mushtaq, et al.. (2025). Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019. Journal of Antimicrobial Chemotherapy. 80(Supplement_4). iv60–iv71. 1 indexed citations
4.
Reynolds, Rosy, Shazad Mushtaq, Olisaeloka Nsonwu, et al.. (2025). The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations. Journal of Antimicrobial Chemotherapy. 80(Supplement_4). iv7–iv21. 5 indexed citations
5.
Parcell, Benjamin J., et al.. (2025). Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future. Journal of Antimicrobial Chemotherapy. 80(Supplement_4). iv87–iv95.
6.
Horner, Carolyne, Rosy Reynolds, Shazad Mushtaq, et al.. (2025). Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019). Journal of Antimicrobial Chemotherapy. 80(Supplement_4). iv72–iv86. 1 indexed citations
7.
Bassetti, Matteo, Gianpaola Monti, Anne Santerre Henriksen, & Christopher Longshaw. (2024). Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy. Antimicrobial Resistance and Infection Control. 13(1). 91–91. 3 indexed citations
8.
Gill, Christian M, Miki Takemura, Christopher Longshaw, et al.. (2023). In vivoefficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versusAcinetobacter baumannii. Journal of Antimicrobial Chemotherapy. 78(4). 983–990. 20 indexed citations
9.
Matuschek, Erika, Christopher Longshaw, Miki Takemura, Yoshinori Yamano, & Gunnar Kahlmeter. (2022). Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy. 77(6). 1662–1669. 45 indexed citations
10.
Goldenberg, Simon, Andrew Dodgson, Gavin Barlow, et al.. (2022). Epidemiology, Outcomes and Resource Utilisation in Patients with Carbapenem Non-susceptible Gram-Negative Bacteria in the UK: A Retrospective, Observational Study (CARBAR UK). Advances in Therapy. 39(8). 3602–3615. 6 indexed citations
11.
Henriksen, Anne Santerre, et al.. (2021). In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany. Journal of Global Antimicrobial Resistance. 28. 12–17. 4 indexed citations
12.
Yamano, Yoshinori, Miki Takemura, Christopher Longshaw, & Roger Echols. (2020). 1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol. Open Forum Infectious Diseases. 7(Supplement_1). S651–S651. 7 indexed citations
13.
Bassetti, Matteo, Jordi Rello, Francesco Blasi, et al.. (2020). Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. International Journal of Antimicrobial Agents. 56(6). 106184–106184. 63 indexed citations
14.
Zasowski, Evan J, Matteo Bassetti, Francesco Blasi, et al.. (2020). A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections. CHEST Journal. 158(3). 929–938. 64 indexed citations
15.
Freeman, Jane, Jon J. Vernon, K. Morris, et al.. (2017). The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011–2014. Clinical Microbiology and Infection. 24(7). 724–731. 106 indexed citations
16.
Chilton, C. H., G. S. Crowther, Helen Ashwin, Christopher Longshaw, & Mark H. Wilcox. (2016). Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production. PLoS ONE. 11(8). e0161200–e0161200. 27 indexed citations
17.
Freeman, Jane, Jon J. Vernon, K. Morris, et al.. (2014). Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clinical Microbiology and Infection. 21(3). 248.e9–248.e16. 217 indexed citations
18.
Chilton, C. H., G. S. Crowther, Jane Freeman, et al.. (2013). Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. Journal of Antimicrobial Chemotherapy. 69(2). 451–462. 41 indexed citations
19.
Bowden, M. Gabriela, Livia Visai, Christopher Longshaw, et al.. (2002). Is the GehD Lipase from Staphylococcus epidermidis a Collagen Binding Adhesin?. Journal of Biological Chemistry. 277(45). 43017–43023. 80 indexed citations
20.
Sandoe, Jonathan & Christopher Longshaw. (2001). Ventriculoperitoneal shunt infection caused by Staphylococcus lugdunensis. Clinical Microbiology and Infection. 7(7). 385–387. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Karlsson Breakdown of academic impact, for papers by Camilla Wiuff Breakdown of academic impact, for papers by Paul Lephart Breakdown of academic impact, for papers by Eduardo Rodríguez-Noriega Breakdown of academic impact, for papers by Deborah C. Draghi Breakdown of academic impact, for papers by Francesco Cristini Breakdown of academic impact, for papers by Rayo Morfín‐Otero Breakdown of academic impact, for papers by Élisabeth Chachaty Breakdown of academic impact, for papers by Mark LaRocco Breakdown of academic impact, for papers by Dee Shortridge
Rankless by CCL
2026